ENSG00000134982 |
|
colorectal adenocarcinoma |
frameshift_variant |
49.18% (2322/4721) |
57 entries |
ENSG00000134982 |
|
colon adenocarcinoma |
sequence_alteration |
47.74% (1182/2476) |
19 entries |
ENSG00000134982 |
|
colorectal neoplasm |
frameshift_variant |
20.93% (104/497) |
2 entries |
ENSG00000134982 |
|
colorectal adenoma |
missense_variant |
49.96% (710/1421) |
3 entries |
ENSG00000134982 |
|
colorectal adenocarcinoma |
conservative_inframe_deletion |
49.18% (2322/4721) |
1 entry |
ENSG00000134982 |
|
rectal adenocarcinoma |
missense_variant |
60.51% (613/1013) |
11 entries |
ENSG00000134982 |
|
Gastric Adenoma |
stop_gained |
33.33% (77/231) |
6 entries |
ENSG00000134982 |
|
Rectal Villous Adenoma |
missense_variant |
83.33% (10/12) |
2 entries |
ENSG00000134982 |
|
colon adenoma |
frameshift_variant |
61.54% (64/104) |
7 entries |
ENSG00000134982 |
|
Ampulla of Vater Carcinoma |
missense_variant |
24.87% (49/197) |
1 entry |
ENSG00000134982 |
|
colorectal adenoma |
stop_gained |
49.96% (710/1421) |
16 entries |
ENSG00000134982 |
|
Rectal Tubulovillous Adenoma |
frameshift_variant |
86.67% (13/15) |
2 entries |
ENSG00000134982 |
|
colorectal adenocarcinoma |
missense_variant |
49.18% (2322/4721) |
39 entries |
ENSG00000134982 |
|
rectum adenoma |
frameshift_variant |
68.42% (13/19) |
2 entries |
ENSG00000134982 |
|
colon adenocarcinoma |
missense_variant |
47.74% (1182/2476) |
22 entries |
ENSG00000134982 |
|
colon adenoma |
sequence_alteration |
61.54% (64/104) |
2 entries |
ENSG00000134982 |
|
colorectal adenoma |
frameshift_variant |
49.96% (710/1421) |
14 entries |
ENSG00000134982 |
|
Rectal Tubular Adenoma |
stop_gained |
62.96% (17/27) |
1 entry |
ENSG00000134982 |
|
rectum adenoma |
stop_gained |
68.42% (13/19) |
3 entries |
ENSG00000134982 |
|
colorectal tubulovillous adenoma |
frameshift_variant |
62.5% (35/56) |
4 entries |
ENSG00000134982 |
|
Rectal Villous Adenoma |
stop_gained |
83.33% (10/12) |
3 entries |
ENSG00000134982 |
|
colonic neoplasm |
stop_gained |
70.0% (14/20) |
1 entry |
ENSG00000134982 |
|
Ampulla of Vater Carcinoma |
stop_gained |
24.87% (49/197) |
1 entry |
ENSG00000134982 |
|
Gastric Adenoma |
frameshift_variant |
33.33% (77/231) |
9 entries |
ENSG00000134982 |
|
rectal adenocarcinoma |
frameshift_variant |
60.51% (613/1013) |
24 entries |
ENSG00000134982 |
|
cecum adenocarcinoma |
missense_variant |
55.73% (219/393) |
9 entries |
ENSG00000134982 |
|
rectal adenocarcinoma |
stop_gained |
60.51% (613/1013) |
30 entries |
ENSG00000134982 |
|
cecum adenocarcinoma |
frameshift_variant |
55.73% (219/393) |
16 entries |
ENSG00000134982 |
|
rectal adenocarcinoma |
sequence_alteration |
60.51% (613/1013) |
8 entries |
ENSG00000134982 |
|
colon adenocarcinoma |
frameshift_variant |
47.74% (1182/2476) |
43 entries |
ENSG00000134982 |
|
colorectal adenoma |
sequence_alteration |
49.96% (710/1421) |
7 entries |
ENSG00000134982 |
|
cecum adenocarcinoma |
stop_gained |
55.73% (219/393) |
14 entries |
ENSG00000134982 |
|
Rectal Villous Adenoma |
frameshift_variant |
83.33% (10/12) |
3 entries |
ENSG00000134982 |
|
Gastric Adenoma |
sequence_alteration |
33.33% (77/231) |
2 entries |
ENSG00000134982 |
|
colorectal adenocarcinoma |
sequence_alteration |
49.18% (2322/4721) |
27 entries |
ENSG00000134982 |
|
cecum adenocarcinoma |
sequence_alteration |
55.73% (219/393) |
2 entries |
ENSG00000134982 |
|
Rectal Tubular Adenoma |
frameshift_variant |
62.96% (17/27) |
4 entries |
ENSG00000134982 |
|
colonic neoplasm |
frameshift_variant |
70.0% (14/20) |
2 entries |
ENSG00000134982 |
|
Rectal Tubulovillous Adenoma |
stop_gained |
86.67% (13/15) |
1 entry |
ENSG00000134982 |
|
colorectal adenoma |
conservative_inframe_deletion |
49.96% (710/1421) |
2 entries |
ENSG00000134982 |
|
Gastric Adenoma |
missense_variant |
33.33% (77/231) |
2 entries |
ENSG00000134982 |
|
colorectal tubulovillous adenoma |
sequence_alteration |
62.5% (35/56) |
2 entries |
ENSG00000134982 |
|
colorectal tubulovillous adenoma |
stop_gained |
62.5% (35/56) |
3 entries |
ENSG00000134982 |
|
Ampulla of Vater Carcinoma |
frameshift_variant |
24.87% (49/197) |
1 entry |
ENSG00000134982 |
|
colorectal adenocarcinoma |
stop_gained |
49.18% (2322/4721) |
61 entries |
ENSG00000134982 |
|
colon adenocarcinoma |
stop_gained |
47.74% (1182/2476) |
52 entries |
ENSG00000134982 |
|
colon adenoma |
stop_gained |
61.54% (64/104) |
8 entries |
ENSG00000134982 |
|
colorectal neoplasm |
stop_gained |
20.93% (104/497) |
3 entries |
ENSG00000134982 |
|
Prostate Small Cell Carcinoma |
frameshift_variant |
15.79% (3/19) |
1 entry |
ENSG00000134982 |
|
Gallbladder Adenocarcinoma |
missense_variant |
3.017% (7/232) |
2 entries |
ENSG00000134982 |
|
esophageal squamous cell carcinoma |
stop_gained |
2.583% (24/929) |
2 entries |
ENSG00000134982 |
|
clear cell renal carcinoma |
sequence_alteration |
0.9793% (17/1736) |
1 entry |
ENSG00000134982 |
|
bladder carcinoma |
frameshift_variant |
4.545% (28/616) |
1 entry |
ENSG00000134982 |
|
lung adenocarcinoma |
stop_gained |
3.746% (121/3230) |
5 entries |
ENSG00000134982 |
|
acute lymphoblastic leukemia |
missense_variant |
0.8264% (3/363) |
2 entries |
ENSG00000134982 |
|
squamous cell lung carcinoma |
missense_variant |
2.317% (25/1079) |
5 entries |
ENSG00000134982 |
|
Rectal Tubulovillous Adenoma |
sequence_alteration |
86.67% (13/15) |
1 entry |
ENSG00000134982 |
|
colonic neoplasm |
sequence_alteration |
70.0% (14/20) |
1 entry |
ENSG00000134982 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
5.997% (46/767) |
3 entries |
ENSG00000134982 |
|
hepatocellular carcinoma |
stop_gained |
2.661% (29/1090) |
3 entries |
ENSG00000134982 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.396% (13/931) |
2 entries |
ENSG00000134982 |
|
polycythemia vera |
missense_variant |
2.609% (3/115) |
2 entries |
ENSG00000134982 |
|
clear cell renal carcinoma |
missense_variant |
0.9793% (17/1736) |
6 entries |
ENSG00000134982 |
|
Signet Ring Cell Gastric Adenocarcinoma |
frameshift_variant |
7.895% (3/38) |
2 entries |
ENSG00000134982 |
|
colon carcinoma |
frameshift_variant |
25.0% (2/8) |
1 entry |
ENSG00000134982 |
|
Ovarian Endometrioid Adenocarcinoma |
frameshift_variant |
9.589% (7/73) |
2 entries |
ENSG00000134982 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
4.386% (5/114) |
4 entries |
ENSG00000134982 |
|
prostate carcinoma |
stop_gained |
3.901% (22/564) |
3 entries |
ENSG00000134982 |
|
gastric adenocarcinoma |
frameshift_variant |
4.46% (97/2175) |
9 entries |
ENSG00000134982 |
|
bladder transitional cell carcinoma |
stop_gained |
4.733% (31/655) |
2 entries |
ENSG00000134982 |
|
prostate carcinoma |
missense_variant |
3.901% (22/564) |
3 entries |
ENSG00000134982 |
|
prostate carcinoma |
frameshift_variant |
3.901% (22/564) |
2 entries |
ENSG00000134982 |
|
Pancreatic Acinar Cell Carcinoma |
missense_variant |
7.609% (7/92) |
2 entries |
ENSG00000134982 |
|
sebaceous adenocarcinoma |
missense_variant |
37.5% (3/8) |
1 entry |
ENSG00000134982 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.9831% (7/712) |
2 entries |
ENSG00000134982 |
|
Colon Juvenile Polyp |
missense_variant |
25.0% (3/12) |
1 entry |
ENSG00000134982 |
|
diffuse gastric adenocarcinoma |
stop_gained |
16.04% (30/187) |
3 entries |
ENSG00000134982 |
|
nasopharyngeal squamous cell carcinoma |
stop_gained |
2.597% (8/308) |
1 entry |
ENSG00000134982 |
|
Pleural Epithelioid Mesothelioma |
frameshift_variant |
1.442% (3/208) |
1 entry |
ENSG00000134982 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
2.765% (12/434) |
2 entries |
ENSG00000134982 |
|
angiosarcoma |
missense_variant |
6.383% (3/47) |
1 entry |
ENSG00000134982 |
|
adrenal cortex carcinoma |
stop_gained |
1.691% (7/414) |
3 entries |
ENSG00000134982 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
4.167% (3/72) |
1 entry |
ENSG00000134982 |
|
chromophobe renal cell carcinoma |
missense_variant |
1.235% (2/162) |
2 entries |
ENSG00000134982 |
|
prostate adenocarcinoma |
missense_variant |
5.326% (120/2253) |
4 entries |
ENSG00000134982 |
|
Hepatoblastoma |
missense_variant |
23.08% (9/39) |
1 entry |
ENSG00000134982 |
|
female breast carcinoma |
missense_variant |
1.518% (9/593) |
5 entries |
ENSG00000134982 |
|
anaplastic astrocytoma |
missense_variant |
2.516% (4/159) |
1 entry |
ENSG00000134982 |
|
follicular thyroid carcinoma |
missense_variant |
3.704% (4/108) |
2 entries |
ENSG00000134982 |
|
Ovarian Endometrioid Adenocarcinoma |
missense_variant |
9.589% (7/73) |
2 entries |
ENSG00000134982 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
5.997% (46/767) |
3 entries |
ENSG00000134982 |
|
breast adenosis |
stop_gained |
16.67% (2/12) |
1 entry |
ENSG00000134982 |
|
lung adenocarcinoma |
frameshift_variant |
3.746% (121/3230) |
6 entries |
ENSG00000134982 |
|
small cell lung carcinoma |
stop_gained |
3.025% (17/562) |
1 entry |
ENSG00000134982 |
|
bile duct adenocarcinoma |
missense_variant |
2.494% (20/802) |
3 entries |
ENSG00000134982 |
|
hepatocellular carcinoma |
missense_variant |
2.661% (29/1090) |
4 entries |
ENSG00000134982 |
|
breast ductal adenocarcinoma |
stop_gained |
3.889% (73/1877) |
3 entries |
ENSG00000134982 |
|
Rectal Traditional Serrated Adenoma |
frameshift_variant |
17.24% (5/29) |
1 entry |
ENSG00000134982 |
|
bladder carcinoma |
missense_variant |
4.545% (28/616) |
1 entry |
ENSG00000134982 |
|
small intestinal adenocarcinoma |
stop_gained |
19.0% (19/100) |
5 entries |
ENSG00000134982 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
10.91% (6/55) |
2 entries |
ENSG00000134982 |
|
Appendix Neuroendocrine Tumor G1 |
missense_variant |
2.128% (2/94) |
1 entry |
ENSG00000134982 |
|
lung adenocarcinoma |
missense_variant |
3.746% (121/3230) |
14 entries |
ENSG00000134982 |
|
esophageal adenocarcinoma |
frameshift_variant |
5.928% (38/641) |
3 entries |
ENSG00000134982 |
|
melanoma |
stop_gained |
3.077% (28/910) |
4 entries |
ENSG00000134982 |
|
rectum adenoma |
sequence_alteration |
68.42% (13/19) |
1 entry |
ENSG00000134982 |
|
papillary thyroid carcinoma |
frameshift_variant |
3.698% (24/649) |
7 entries |
ENSG00000134982 |
|
oral squamous cell carcinoma |
missense_variant |
2.477% (8/323) |
4 entries |
ENSG00000134982 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
2.658% (16/602) |
2 entries |
ENSG00000134982 |
|
Appendix Adenocarcinoma |
stop_gained |
1.431% (8/559) |
2 entries |
ENSG00000134982 |
|
skin melanoma |
missense_variant |
6.061% (76/1254) |
10 entries |
ENSG00000134982 |
|
anaplastic oligodendroglioma |
missense_variant |
4.082% (4/98) |
2 entries |
ENSG00000134982 |
|
Bladder Adenocarcinoma |
stop_gained |
13.64% (3/22) |
2 entries |
ENSG00000134982 |
|
brain glioblastoma |
frameshift_variant |
1.845% (28/1518) |
2 entries |
ENSG00000134982 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
5.997% (46/767) |
2 entries |
ENSG00000134982 |
|
Duodenal Adenocarcinoma |
stop_gained |
18.29% (15/82) |
2 entries |
ENSG00000134982 |
|
esophageal carcinoma |
frameshift_variant |
1.363% (14/1027) |
1 entry |
ENSG00000134982 |
|
endometrial carcinoma |
stop_gained |
5.0% (4/80) |
3 entries |
ENSG00000134982 |
|
squamous cell lung carcinoma |
sequence_alteration |
2.317% (25/1079) |
1 entry |
ENSG00000134982 |
|
Dysplasia in Ulcerative Colitis |
missense_variant |
37.5% (3/8) |
1 entry |
ENSG00000134982 |
|
mucosal melanoma |
missense_variant |
4.286% (3/70) |
1 entry |
ENSG00000134982 |
|
pancreatic neuroendocrine tumor |
missense_variant |
3.689% (9/244) |
3 entries |
ENSG00000134982 |
|
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
2.597% (8/308) |
1 entry |
ENSG00000134982 |
|
cervical squamous cell carcinoma |
missense_variant |
2.286% (8/350) |
1 entry |
ENSG00000134982 |
|
breast ductal adenocarcinoma |
missense_variant |
3.889% (73/1877) |
3 entries |
ENSG00000134982 |
|
small intestinal adenocarcinoma |
frameshift_variant |
19.0% (19/100) |
5 entries |
ENSG00000134982 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.6378% (5/784) |
2 entries |
ENSG00000134982 |
|
colorectal neoplasm |
amino_acid_insertion |
20.93% (104/497) |
1 entry |
ENSG00000134982 |
|
acute myeloid leukemia |
missense_variant |
0.5274% (5/948) |
1 entry |
ENSG00000134982 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
6.699% (14/209) |
3 entries |
ENSG00000134982 |
|
lung adenocarcinoma |
sequence_alteration |
3.746% (121/3230) |
4 entries |
ENSG00000134982 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
7.117% (20/281) |
4 entries |
ENSG00000134982 |
|
papillary thyroid carcinoma |
missense_variant |
3.698% (24/649) |
2 entries |
ENSG00000134982 |
|
Pleural Mesothelioma |
missense_variant |
1.351% (2/148) |
2 entries |
ENSG00000134982 |
|
ulcerative colitis |
missense_variant |
3.448% (2/58) |
1 entry |
ENSG00000134982 |
|
Gallbladder Adenocarcinoma |
stop_gained |
3.017% (7/232) |
2 entries |
ENSG00000134982 |
|
ameloblastoma |
missense_variant |
12.0% (3/25) |
1 entry |
ENSG00000134982 |
|
adrenal cortex carcinoma |
frameshift_variant |
1.691% (7/414) |
2 entries |
ENSG00000134982 |
|
prostate adenocarcinoma |
stop_gained |
5.326% (120/2253) |
4 entries |
ENSG00000134982 |
|
adrenal cortex carcinoma |
missense_variant |
1.691% (7/414) |
2 entries |
ENSG00000134982 |
|
ovarian teratoma |
missense_variant |
6.897% (4/58) |
1 entry |
ENSG00000134982 |
|
urothelial carcinoma |
missense_variant |
3.488% (3/86) |
1 entry |
ENSG00000134982 |
|
skin carcinoma |
missense_variant |
7.692% (8/104) |
1 entry |
ENSG00000134982 |
|
rectal neoplasm |
stop_gained |
80.0% (4/5) |
1 entry |
ENSG00000134982 |
|
basal cell carcinoma |
missense_variant |
9.639% (8/83) |
2 entries |
ENSG00000134982 |
|
skin melanoma |
frameshift_variant |
6.061% (76/1254) |
2 entries |
ENSG00000134982 |
|
metaplastic breast carcinoma |
stop_gained |
4.795% (7/146) |
2 entries |
ENSG00000134982 |
|
female breast carcinoma |
sequence_alteration |
1.518% (9/593) |
1 entry |
ENSG00000134982 |
|
papillary renal cell carcinoma |
missense_variant |
0.7732% (3/388) |
1 entry |
ENSG00000134982 |
|
squamous cell lung carcinoma |
stop_gained |
2.317% (25/1079) |
2 entries |
ENSG00000134982 |
|
hepatocellular carcinoma |
sequence_alteration |
2.661% (29/1090) |
1 entry |
ENSG00000134982 |
|
non-small cell lung carcinoma |
frameshift_variant |
1.312% (10/762) |
1 entry |
ENSG00000134982 |
|
prostate adenocarcinoma |
sequence_alteration |
5.326% (120/2253) |
1 entry |
ENSG00000134982 |
|
colon adenoma |
missense_variant |
61.54% (64/104) |
1 entry |
ENSG00000134982 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
3.12% (64/2051) |
6 entries |
ENSG00000134982 |
|
non-small cell lung carcinoma |
missense_variant |
1.312% (10/762) |
5 entries |
ENSG00000134982 |
|
gastric adenocarcinoma |
stop_gained |
4.46% (97/2175) |
9 entries |
ENSG00000134982 |
|
metaplastic breast carcinoma |
missense_variant |
4.795% (7/146) |
1 entry |
ENSG00000134982 |
|
cervical carcinoma |
missense_variant |
12.5% (3/24) |
2 entries |
ENSG00000134982 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
2.765% (12/434) |
5 entries |
ENSG00000134982 |
|
brain glioblastoma |
missense_variant |
1.845% (28/1518) |
6 entries |
ENSG00000134982 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
18.29% (15/82) |
2 entries |
ENSG00000134982 |
|
melanoma |
missense_variant |
3.077% (28/910) |
6 entries |
ENSG00000134982 |
|
skin melanoma |
stop_gained |
6.061% (76/1254) |
2 entries |
ENSG00000134982 |
|
gastric adenocarcinoma |
missense_variant |
4.46% (97/2175) |
6 entries |
ENSG00000134982 |
|
small intestinal adenocarcinoma |
missense_variant |
19.0% (19/100) |
2 entries |
ENSG00000134982 |
|
papillary thyroid carcinoma |
stop_gained |
3.698% (24/649) |
2 entries |
ENSG00000134982 |
|
adenosquamous lung carcinoma |
missense_variant |
6.897% (2/29) |
2 entries |
ENSG00000134982 |
|
urothelial carcinoma |
stop_gained |
3.488% (3/86) |
1 entry |
ENSG00000134982 |
|
breast carcinoma |
missense_variant |
1.258% (25/1988) |
5 entries |
ENSG00000134982 |
|
bile duct adenocarcinoma |
stop_gained |
2.494% (20/802) |
3 entries |
ENSG00000134982 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
3.12% (64/2051) |
1 entry |
ENSG00000134982 |
|
melanoma |
frameshift_variant |
3.077% (28/910) |
1 entry |
ENSG00000134982 |
|
Pancreatic Acinar Cell Carcinoma |
frameshift_variant |
7.609% (7/92) |
2 entries |
ENSG00000134982 |
|
small cell lung carcinoma |
missense_variant |
3.025% (17/562) |
4 entries |
ENSG00000134982 |
|
breast carcinoma |
frameshift_variant |
1.258% (25/1988) |
1 entry |
ENSG00000134982 |
|
breast carcinoma |
stop_gained |
1.258% (25/1988) |
1 entry |
ENSG00000134982 |
|
Merkel cell skin cancer |
missense_variant |
3.509% (6/171) |
2 entries |
ENSG00000134982 |
|
gastric intestinal type adenocarcinoma |
stop_gained |
7.117% (20/281) |
3 entries |
ENSG00000134982 |
|
diffuse gastric adenocarcinoma |
missense_variant |
16.04% (30/187) |
2 entries |
ENSG00000134982 |
|
colorectal tubulovillous adenoma |
missense_variant |
62.5% (35/56) |
1 entry |
ENSG00000134982 |
|
breast ductal adenocarcinoma |
sequence_alteration |
3.889% (73/1877) |
1 entry |
ENSG00000134982 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.597% (8/308) |
2 entries |
ENSG00000134982 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
3.12% (64/2051) |
1 entry |
ENSG00000134982 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
60.51% (613/1013) |
1 entry |
ENSG00000134982 |
|
chronic lymphocytic leukemia |
sequence_alteration |
0.8979% (8/891) |
1 entry |
ENSG00000134982 |
|
colon adenocarcinoma |
amino_acid_insertion |
47.74% (1182/2476) |
1 entry |
ENSG00000134982 |
|
gastric adenocarcinoma |
sequence_alteration |
4.46% (97/2175) |
2 entries |
ENSG00000134982 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
3.017% (7/232) |
1 entry |
ENSG00000134982 |
|
Ileal Neuroendocrine Tumor G1 |
missense_variant |
28.57% (2/7) |
1 entry |
ENSG00000134982 |
|
colonic neoplasm |
missense_variant |
70.0% (14/20) |
1 entry |
ENSG00000134982 |
|
Gastric Neuroendocrine Tumor G1 |
missense_variant |
17.65% (3/17) |
1 entry |
ENSG00000134982 |
|
breast ductal adenocarcinoma |
frameshift_variant |
3.889% (73/1877) |
4 entries |
ENSG00000134982 |
|
squamous cell lung carcinoma |
frameshift_variant |
2.317% (25/1079) |
2 entries |
ENSG00000134982 |
|
Appendix Adenocarcinoma |
missense_variant |
1.431% (8/559) |
1 entry |
ENSG00000134982 |
|
esophageal adenocarcinoma |
missense_variant |
5.928% (38/641) |
3 entries |
ENSG00000134982 |
|
hepatocellular carcinoma |
frameshift_variant |
2.661% (29/1090) |
3 entries |
ENSG00000134982 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
3.12% (64/2051) |
4 entries |
ENSG00000134982 |
|
esophageal carcinoma |
missense_variant |
1.363% (14/1027) |
1 entry |
ENSG00000134982 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
7.117% (20/281) |
4 entries |
ENSG00000134982 |
|
skin melanoma |
sequence_alteration |
6.061% (76/1254) |
2 entries |
ENSG00000134982 |
|
small cell lung carcinoma |
frameshift_variant |
3.025% (17/562) |
2 entries |
ENSG00000134982 |
|
Rectal Traditional Serrated Adenoma |
stop_gained |
17.24% (5/29) |
1 entry |
ENSG00000134982 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
2.658% (16/602) |
2 entries |
ENSG00000134982 |
|
esophageal squamous cell carcinoma |
missense_variant |
2.583% (24/929) |
8 entries |
ENSG00000134982 |
|
lobular breast carcinoma |
missense_variant |
2.318% (7/302) |
1 entry |
ENSG00000134982 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
47.74% (1182/2476) |
1 entry |
ENSG00000134982 |
|
colorectal adenocarcinoma |
amino_acid_insertion |
49.18% (2322/4721) |
1 entry |
ENSG00000134982 |
|
esophageal adenocarcinoma |
stop_gained |
5.928% (38/641) |
4 entries |
ENSG00000134982 |
|
brain glioblastoma |
sequence_alteration |
1.845% (28/1518) |
2 entries |
ENSG00000134982 |
|
kidney Wilms tumor |
stop_gained |
1.133% (4/353) |
1 entry |
ENSG00000134982 |
|
HER2 Positive Breast Carcinoma |
sequence_alteration |
6.699% (14/209) |
1 entry |
ENSG00000134982 |
|
colon carcinoma |
stop_gained |
25.0% (2/8) |
1 entry |
ENSG00000134982 |
|
prostate adenocarcinoma |
frameshift_variant |
5.326% (120/2253) |
4 entries |
ENSG00000134982 |
|
bladder transitional cell carcinoma |
missense_variant |
4.733% (31/655) |
6 entries |
ENSG00000134982 |
|
bile duct adenocarcinoma |
frameshift_variant |
2.494% (20/802) |
3 entries |
ENSG00000134982 |
|
diffuse large B-cell lymphoma |
missense_variant |
2.66% (10/376) |
6 entries |
ENSG00000134982 |
|
Rectal Tubular Adenoma |
missense_variant |
62.96% (17/27) |
1 entry |
ENSG00000134982 |
|
hemangioblastoma |
sequence_alteration |
8.571% (3/35) |
1 entry |
ENSG00000134982 |
|
Duodenal Adenocarcinoma |
missense_variant |
18.29% (15/82) |
3 entries |
ENSG00000134982 |
|
Mixed Lobular and Ductal Breast Carcinoma |
stop_gained |
1.449% (1/69) |
1 entry |
ENSG00000134982 |
|
Ovarian Microcystic Stromal Tumor |
missense_variant |
100.0% (2/2) |
1 entry |
ENSG00000134982 |
|
adrenocortical adenoma |
sequence_alteration |
3.704% (2/54) |
1 entry |
ENSG00000134982 |
|
epidermal appendage tumor |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000134982 |
|
Ameloblastic Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000134982 |
|
angioimmunoblastic T-cell lymphoma |
frameshift_variant |
2.804% (3/107) |
1 entry |
ENSG00000134982 |
|
bladder transitional cell carcinoma |
frameshift_variant |
4.733% (31/655) |
1 entry |
ENSG00000134982 |
|
bile duct adenocarcinoma |
sequence_alteration |
2.494% (20/802) |
1 entry |
ENSG00000134982 |
|
Benign Thyroid Gland Neoplasm |
missense_variant |
0.9259% (1/108) |
1 entry |
ENSG00000134982 |
|
diffuse large B-cell lymphoma |
stop_lost |
2.66% (10/376) |
1 entry |
ENSG00000134982 |
|
adenoma of small intestine |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000134982 |
|
clear cell renal carcinoma |
stop_gained |
0.9793% (17/1736) |
1 entry |
ENSG00000134982 |
|
Malignant Ovarian Mixed Epithelial Tumor |
sequence_alteration |
16.67% (1/6) |
1 entry |
ENSG00000134982 |
|
Angiofibroma |
frameshift_variant |
20.0% (1/5) |
1 entry |
ENSG00000134982 |
|
Eccrine Porocarcinoma |
missense_variant |
6.25% (1/16) |
1 entry |
ENSG00000134982 |
|
Appendix Adenocarcinoma |
frameshift_variant |
1.431% (8/559) |
1 entry |
ENSG00000134982 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
frameshift_variant |
2.765% (12/434) |
1 entry |
ENSG00000134982 |
|
Adrenal Gland Neuroblastoma |
sequence_alteration |
3.333% (2/60) |
1 entry |
ENSG00000134982 |
|
Colon Neuroendocrine Tumor G1 |
frameshift_variant |
20.0% (1/5) |
1 entry |
ENSG00000134982 |
|
Pancreatic Acinar Cell Carcinoma |
stop_gained |
7.609% (7/92) |
1 entry |
ENSG00000134982 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
0.6378% (5/784) |
1 entry |
ENSG00000134982 |
|
endometrial carcinoma |
sequence_alteration |
5.0% (4/80) |
1 entry |
ENSG00000134982 |
|
Ovarian Microcystic Stromal Tumor |
frameshift_variant |
100.0% (2/2) |
1 entry |
ENSG00000134982 |
|
tumor of duodenum |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000134982 |
|
Parathyroid Gland Carcinoma |
missense_variant |
5.263% (1/19) |
1 entry |
ENSG00000134982 |
|
Ovarian Mixed Epithelial Tumor |
sequence_alteration |
100.0% (1/1) |
1 entry |
ENSG00000134982 |
|
large cell medulloblastoma |
missense_variant |
2.778% (1/36) |
1 entry |
ENSG00000134982 |
|
breast ductal adenocarcinoma |
conservative_inframe_deletion |
3.889% (73/1877) |
1 entry |
ENSG00000134982 |
|
Ovarian Endometrioid Adenocarcinoma |
stop_gained |
9.589% (7/73) |
1 entry |
ENSG00000134982 |
|
salivary gland adenoid cystic carcinoma |
frameshift_variant |
3.125% (3/96) |
1 entry |
ENSG00000134982 |
|
desmoplastic fibroma |
stop_gained |
50.0% (1/2) |
1 entry |
ENSG00000134982 |
|
myelodysplastic syndrome |
missense_variant |
0.7692% (1/130) |
1 entry |
ENSG00000134982 |
|
neoplasm |
stop_gained |
2.326% (1/43) |
1 entry |
ENSG00000134982 |
|
Invasive Breast Carcinoma |
missense_variant |
2.857% (2/70) |
1 entry |
ENSG00000134982 |
|
alveolar rhabdomyosarcoma |
missense_variant |
1.538% (1/65) |
1 entry |
ENSG00000134982 |
|
Vulvar Squamous Cell Carcinoma |
missense_variant |
2.0% (1/50) |
1 entry |
ENSG00000134982 |
|
Ocular Sebaceous Carcinoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000134982 |
|
carcinoma |
frameshift_variant |
25.0% (1/4) |
1 entry |
ENSG00000134982 |
|
papillary renal cell carcinoma |
stop_gained |
0.7732% (3/388) |
1 entry |
ENSG00000134982 |
|
Adrenal Gland Neuroblastoma |
missense_variant |
3.333% (2/60) |
1 entry |
ENSG00000134982 |
|
renal carcinoma |
missense_variant |
5.0% (1/20) |
1 entry |
ENSG00000134982 |
|
follicular thyroid carcinoma |
frameshift_variant |
3.704% (4/108) |
1 entry |
ENSG00000134982 |
|
solitary fibrous tumor |
missense_variant |
3.226% (1/31) |
1 entry |
ENSG00000134982 |
|
large cell lung carcinoma |
stop_gained |
1.887% (1/53) |
1 entry |
ENSG00000134982 |
|
angiosarcoma |
sequence_alteration |
6.383% (3/47) |
1 entry |
ENSG00000134982 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
2.597% (8/308) |
1 entry |
ENSG00000134982 |
|
colon carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000134982 |
|
carcinosarcoma |
stop_gained |
33.33% (1/3) |
1 entry |
ENSG00000134982 |
|
Rectal Traditional Serrated Adenoma |
sequence_alteration |
17.24% (5/29) |
1 entry |
ENSG00000134982 |
|
Poroma |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000134982 |
|
salivary gland adenoid cystic carcinoma |
stop_gained |
3.125% (3/96) |
1 entry |
ENSG00000134982 |
|
desmoplastic small round cell tumor |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000134982 |
|
Primary Intraosseous Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000134982 |
|
lung carcinoid tumor |
missense_variant |
2.857% (1/35) |
1 entry |
ENSG00000134982 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
0.5848% (1/171) |
1 entry |
ENSG00000134982 |
|
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
2.658% (16/602) |
1 entry |
ENSG00000134982 |
|
Testicular Yolk Sac Tumor |
stop_gained |
11.11% (1/9) |
1 entry |
ENSG00000134982 |
|
Kidney Oncocytoma |
missense_variant |
2.326% (1/43) |
1 entry |
ENSG00000134982 |
|
Thymoma |
stop_gained |
0.7194% (1/139) |
1 entry |
ENSG00000134982 |
|
adrenocortical adenoma |
frameshift_variant |
3.704% (2/54) |
1 entry |
ENSG00000134982 |
|
desmoplastic medulloblastoma |
stop_gained |
2.564% (1/39) |
1 entry |
ENSG00000134982 |
|
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
4.386% (5/114) |
1 entry |
ENSG00000134982 |
|
anaplastic astrocytoma |
stop_gained |
2.516% (4/159) |
1 entry |
ENSG00000134982 |
|
central nervous system primitive neuroectodermal neoplasm |
stop_gained |
0.9831% (7/712) |
1 entry |
ENSG00000134982 |
|
Pleural Biphasic Mesothelioma |
stop_gained |
1.333% (1/75) |
1 entry |
ENSG00000134982 |
|
astrocytoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000134982 |
|
villous adenoma of colon |
frameshift_variant |
11.11% (1/9) |
1 entry |
ENSG00000134982 |
|
bronchoalveolar adenocarcinoma |
stop_gained |
4.545% (1/22) |
1 entry |
ENSG00000134982 |
|
metaplastic breast carcinoma |
frameshift_variant |
4.795% (7/146) |
1 entry |
ENSG00000134982 |
|
thyroid carcinoma |
frameshift_variant |
1.606% (15/934) |
1 entry |
ENSG00000134982 |
|
neuroendocrine carcinoma |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000134982 |
|
Extraskeletal Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor |
frameshift_variant |
2.941% (1/34) |
1 entry |
ENSG00000134982 |
|
Kidney Angiomyolipoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000134982 |
|
Ovarian Mixed Epithelial Tumor |
frameshift_variant |
100.0% (1/1) |
1 entry |
ENSG00000134982 |
|
oral squamous cell carcinoma |
stop_gained |
2.477% (8/323) |
1 entry |
ENSG00000134982 |
|
Bladder Adenocarcinoma |
frameshift_variant |
13.64% (3/22) |
1 entry |
ENSG00000134982 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma |
missense_variant |
2.703% (1/37) |
1 entry |
ENSG00000134982 |
|
HER2 Positive Breast Carcinoma |
stop_gained |
6.699% (14/209) |
1 entry |
ENSG00000134982 |
|
salivary gland adenoid cystic carcinoma |
missense_variant |
3.125% (3/96) |
1 entry |
ENSG00000134982 |
|
Rhabdoid Meningioma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000134982 |
|
Chordoma |
missense_variant |
2.857% (1/35) |
1 entry |
ENSG00000134982 |
|
Gastric Neuroendocrine Tumor G1 |
frameshift_variant |
17.65% (3/17) |
1 entry |
ENSG00000134982 |
|
medulloblastoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000134982 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
0.8929% (1/112) |
1 entry |
ENSG00000134982 |
|
non-small cell lung carcinoma |
conservative_inframe_deletion |
1.312% (10/762) |
1 entry |
ENSG00000134982 |
|
brain glioblastoma |
conservative_inframe_deletion |
1.845% (28/1518) |
1 entry |
ENSG00000134982 |
|
Gastrointestinal stromal tumor |
missense_variant |
0.6579% (1/152) |
1 entry |
ENSG00000134982 |
|
rectal neoplasm |
missense_variant |
80.0% (4/5) |
1 entry |
ENSG00000134982 |
|
lobular breast carcinoma |
stop_gained |
2.318% (7/302) |
1 entry |
ENSG00000134982 |
|
Prostate Small Cell Carcinoma |
sequence_alteration |
15.79% (3/19) |
1 entry |
ENSG00000134982 |
|
glioma |
frameshift_variant |
0.3333% (2/600) |
1 entry |
ENSG00000134982 |
|
Gallbladder Adenocarcinoma |
frameshift_variant |
3.017% (7/232) |
1 entry |
ENSG00000134982 |
|
head and neck squamous cell carcinoma |
stop_gained |
0.6378% (5/784) |
1 entry |
ENSG00000134982 |
|
central nervous system primitive neuroectodermal neoplasm |
conservative_inframe_deletion |
0.9831% (7/712) |
1 entry |
ENSG00000134982 |
|
esophageal carcinoma |
stop_gained |
1.363% (14/1027) |
1 entry |
ENSG00000134982 |
|
Uterine Carcinosarcoma |
conservative_inframe_deletion |
1.087% (2/184) |
1 entry |
ENSG00000134982 |
|
leiomyosarcoma |
missense_variant |
0.8475% (1/118) |
1 entry |
ENSG00000134982 |
|
Liver Cavernous Hemangioma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000134982 |
|
T-cell acute lymphoblastic leukemia |
conservative_inframe_deletion |
2.658% (16/602) |
1 entry |
ENSG00000134982 |
|
Crohn's disease |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000134982 |
|
basal cell carcinoma |
stop_gained |
9.639% (8/83) |
1 entry |
ENSG00000134982 |
|
Dysplasia in Ulcerative Colitis |
stop_gained |
37.5% (3/8) |
1 entry |
ENSG00000134982 |
|
liposarcoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000134982 |
|
undifferentiated pleomorphic sarcoma |
stop_gained |
4.167% (3/72) |
1 entry |
ENSG00000134982 |
|
endometrial carcinoma |
frameshift_variant |
5.0% (4/80) |
1 entry |
ENSG00000134982 |
|
Thymic Carcinoma |
missense_variant |
6.667% (1/15) |
1 entry |
ENSG00000134982 |
|
angioimmunoblastic T-cell lymphoma |
conservative_inframe_deletion |
2.804% (3/107) |
1 entry |
ENSG00000134982 |
|
mucosal melanoma |
stop_gained |
4.286% (3/70) |
1 entry |
ENSG00000134982 |
|
Merkel cell skin cancer |
stop_gained |
3.509% (6/171) |
1 entry |
ENSG00000134982 |
|
salivary gland squamous cell carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000134982 |
|
ovarian serous adenocarcinoma |
stop_gained |
1.396% (13/931) |
1 entry |
ENSG00000134982 |
|
Signet Ring Cell Gastric Adenocarcinoma |
missense_variant |
7.895% (3/38) |
1 entry |
ENSG00000134982 |
|
malignant epithelioid mesothelioma |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000134982 |
|
ossifying fibroma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000134982 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
2.583% (24/929) |
1 entry |
ENSG00000134982 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
5.326% (120/2253) |
1 entry |
ENSG00000134982 |
|
Appendix Goblet Cell Carcinoid |
stop_gained |
4.762% (1/21) |
1 entry |
ENSG00000134982 |
|
Hepatoblastoma |
frameshift_variant |
23.08% (9/39) |
1 entry |
ENSG00000134982 |
|
brain glioblastoma |
stop_gained |
1.845% (28/1518) |
1 entry |
ENSG00000134982 |
|
Anal Squamous Cell Carcinoma |
missense_variant |
1.205% (1/83) |
1 entry |
ENSG00000134982 |
|
ependymoma |
missense_variant |
1.053% (1/95) |
1 entry |
ENSG00000134982 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
4.46% (97/2175) |
1 entry |
ENSG00000134982 |
|
non-small cell lung carcinoma |
stop_gained |
1.312% (10/762) |
1 entry |
ENSG00000134982 |
|
central nervous system primitive neuroectodermal neoplasm |
frameshift_variant |
0.9831% (7/712) |
1 entry |
ENSG00000134982 |
|
Invasive Breast Carcinoma |
stop_gained |
2.857% (2/70) |
1 entry |
ENSG00000134982 |
|
Uterine Carcinosarcoma |
frameshift_variant |
1.087% (2/184) |
1 entry |
ENSG00000134982 |
|
hepatocellular adenoma |
frameshift_variant |
8.333% (1/12) |
1 entry |
ENSG00000134982 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
missense_variant |
1.575% (2/127) |
1 entry |
ENSG00000134982 |
|
kidney Wilms tumor |
frameshift_variant |
1.133% (4/353) |
1 entry |
ENSG00000134982 |
|
Parotid Gland Squamous Cell Carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000134982 |
|
alveolar soft part sarcoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000134982 |
|
multiple myeloma |
frameshift_variant |
0.5587% (1/179) |
1 entry |
ENSG00000134982 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
1.442% (3/208) |
1 entry |
ENSG00000134982 |
|
lung adenocarcinoma |
amino_acid_insertion |
3.746% (121/3230) |
1 entry |
ENSG00000134982 |
|
angioimmunoblastic T-cell lymphoma |
missense_variant |
2.804% (3/107) |
1 entry |
ENSG00000134982 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
stop_gained |
1.575% (2/127) |
1 entry |
ENSG00000134982 |
|
Epidermal Inclusion Cyst |
sequence_alteration |
50.0% (1/2) |
1 entry |